<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Timothy Devos</style></author><author><style face="normal" font="default" size="100%">Quentin Van Thillo</style></author><author><style face="normal" font="default" size="100%">Veerle Compernolle</style></author><author><style face="normal" font="default" size="100%">Najdovski, Tomé</style></author><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Nicolas Dauby</style></author><author><style face="normal" font="default" size="100%">Laurent Jadot</style></author><author><style face="normal" font="default" size="100%">Mathias Leys</style></author><author><style face="normal" font="default" size="100%">Evelyne Maillart</style></author><author><style face="normal" font="default" size="100%">Sarah Loof</style></author><author><style face="normal" font="default" size="100%">Lucie Seyler</style></author><author><style face="normal" font="default" size="100%">Martial Moonen</style></author><author><style face="normal" font="default" size="100%">Moutschen, Michel</style></author><author><style face="normal" font="default" size="100%">Niels Van Regenmortel</style></author><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author><author><style face="normal" font="default" size="100%">Cyril Barbezange</style></author><author><style face="normal" font="default" size="100%">Albrecht Betrains</style></author><author><style face="normal" font="default" size="100%">Mutien Garigliany</style></author><author><style face="normal" font="default" size="100%">Matthias M Engelen</style></author><author><style face="normal" font="default" size="100%">Iwein Gyselinck</style></author><author><style face="normal" font="default" size="100%">Piet Maes</style></author><author><style face="normal" font="default" size="100%">Alexander Schauwvlieghe</style></author><author><style face="normal" font="default" size="100%">Laurens Liesenborghs</style></author><author><style face="normal" font="default" size="100%">Ann Belmans</style></author><author><style face="normal" font="default" size="100%">Peter Verhamme</style></author><author><style face="normal" font="default" size="100%">Geert Meyfroidt</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">DAWn-plasma investigators</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Respir J</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Aug 26</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥1/320 was the product of choice for the study.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Between May 2nd, 2020 and January 26th, 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median volume of 884 mL convalescent plasma (IQR 806-906 mL) was administered, and 80.68% of the units came from donors with neutralising-antibody-titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on Day 15 was not different between both groups (convalescent plasma: 83.74% (n=267) control: 84.05% (n=137) - Odds ratio 0.99 (0.59-1.66) - p-value=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms, and transfusion-related side effects were reported in 19/320 patients in the intervention group (5.94%).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Transfusion of 4 units of convalescent plasma with high neutralising-antibody-titres early in hospitalised COVID-19 patients did not result in a significant improvement of the clinical status, or a reduced mortality.&lt;/p&gt;
</style></abstract></record></records></xml>